596 AMBER, Part 2B: a phase 1 study of cobolimab plus dostarlimab in patients with advanced/metastatic non-small cell lung cancer (NSCLC) previously treated with anti-PD(L)-1 therapy

• Antoni Ribas,
• Mohammed Milhem,
• Diwakar Davar,
• Patricia LoRusso,
• Zeynep Eroglu,
• Martin Gutierrez,
• Arindam Dhar,
• Carlos Becerra,
• Brian Di Pace,
• Tianli Wang,
• Hailei Zhang,
• Srimoyee Ghosh,
• Shyam Srivats,
• Theo Borgovan,
• Angela Waszak

Affiliations

Antoni Ribas

6University of California Los Angeles, Los Angeles, CA, USA

Mohammed Milhem

The University of Iowa Hospitals and Clinics, Iowa City, Iowa, USA

Diwakar Davar

UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, USA

Patricia LoRusso

9Yale University, New Haven, CT, USA

Zeynep Eroglu

1H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA

Martin Gutierrez

Hackensack University Medical Center, Hackensack, New Jersey, USA

Arindam Dhar

7GSK, Collegeville, PA, USA

Carlos Becerra

4The US Oncology Network, Dallas, TX, USA

Brian Di Pace

7GSK, Collegeville, PA, USA

Tianli Wang

8GSK, Waltham, MA, USA

Hailei Zhang

8GSK, Waltham, MA, USA

Srimoyee Ghosh

8GSK, Waltham, MA, USA

Shyam Srivats

7GSK, Collegeville, PA, USA

Theo Borgovan

8GSK, Waltham, MA, USA

Angela Waszak

8GSK, Waltham, MA, USA